142 95

Cited 1 times in

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab

Authors
 Yong Tae Kim  ;  Jina Kim  ;  Jinsil Seong 
Citation
 Journal of Liver Cancer(대한간암학회지), Vol.23(1) : 225-229, 2023-03 
Journal Title
Journal of Liver Cancer(대한간암학회지)
ISSN
 2288-8128 
Issue Date
2023-03
Keywords
Atezolizumab ; Bevacizumab ; Case reports ; Hepatocellular carcinoma ; Radiotherapy
Abstract
Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with advanced HCC are still being treated in a palliative setting. Radiotherapy (RT) is known to induce immunogenic effects that may enhance the therapeutic efficacy of immune checkpoint inhibitors. Herein, we report the case of a patient with advanced HCC with massive portal vein tumor thrombosis treated with a combination of RT and AteBeva, who showed near complete response in tumor thrombosis and favorable response to HCC. Although this is a rare case, it shows the importance of reducing the tumor burden via RT to combination immunotherapy in patients with advanced HCC.
Files in This Item:
T202307010.pdf Download
DOI
10.17998/jlc.2023.02.27
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jina(김진아)
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/197670
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links